Indian markets are likely to witness a quiet start on Thursday; stalking moderate gains in the Asian stocks. However, as the day progresses, one can witness some volatility moves, especially in the banking stocks as Supreme Court of India is set to resume hearing on loan moratorium. Meanwhile, SGX Nifty is up by 10 points at 11,316 levels.

The stock price has surged 35 per cent within the last one month. Its better-than-expected volume performance, the company's foray into new business such as anti-microbial coated steel products, and better utilisation levels might have helped the gains.

Domestic AUM increased by 1.4 per cent on a sequential basis in the month of August 2020, despite outflows of Rs 4,000 crore from equity dedicated mutual fund.

RMI comes at an appropriate time when remote working has become the new normal due to COVID-19 as the solution when deployed near factory set up can give faster results.

The consolidated net profit in Q1FY21 came in at Rs 24.98 crore, which rose by 261.51 per cent, as compared to Q1FY20, when it reported a profit of Rs 6.91 crore.

The price-to-earnings ratio is the relationship between the current share price and earnings per share (EPS). It is the ratio between the current share price and EPS. This ratio is also known as price multiple or earnings multiple. Usually, for this, the earnings of a company of the last 12 months or one year are used.

Financial ratios are mathematical relationships between two entities, accounts or categories. These relationships between the various accounts in the financial statements help all concerned stakeholders to understand the performance of a company and also helps understand those areas that need improvement.

On Wednesday, Sensex closed at 38,193.92, declining by 171.43 points or 0.45 per cent while Nifty fell by 39.35 points or 0.35 per cent to settle at 11,278. In today’s session, banks, financial, and realty stocks witnessed a major sell-off.

Zydus Cadila informed the exchanges on Wednesday that it has received tentative approval from United States Food & Drug Administration (USFDA) to market Empagliflozin and Linagliptin tablets (US RLD: Glyxambi tablets) in the strengths of 10 mg/5 mg and 25 mg/5 mg.

During Wednesday’s trading session, gold prices slipped again as profit booking was seen across equities. Sensex was in negative territory, down by more than 300 points.